RESUMO
To study socio-demographic and clinical aspects, as well as psychiatric co-morbidity that influence the quality of life of adult epileptic patients. One hundred and thirty-two individuals diagnosed with epilepsy were evaluated from neurological/clinical and psychiatric points of view and by the Quality of Life in Epilepsy Inventory (QOLIE-31). Predictive factors for the QOLIE-31 scores were studied. The regression analyses indicated the existence of psychiatric co-morbidity (total score, seizure worry, emotional well-being, energy/fatigue, social function and cognitive function) and a greater seizure frequency (total score, cognitive function and energy/fatigue) as predictive factors for lower scores in the total QOLIE-31 score and in various dimensions. Abnormalities in the neurological exam and poly-therapy with anti-epileptic drugs were negative factors limited to one of the dimensions cognitive function and social function, respectively. The presence of psychiatric co-morbidity and a greater seizure frequency were the main factors influencing the quality of life in epileptic patients as evaluated by QOLIE-31.
Estudar os aspectos sociodemográficos, clínicos e comorbidades psiquiátricas que influenciam a qualidade de vida de pacientes adultos com epilepsia. Cento e trinta e dois indivíduos com diagnóstico de epilepsia foram avaliados do ponto de vista clínico-neurológico e psiquiátrico e pelo As análises de regressão indicaram a existência de comorbidade psiquiátrica (escore total, crises epilépticas, bem-estar emocional, energia/fadiga, função social e cognição) e a maior frequência de crises (escore total, cognição e energia/fadiga) como fatores preditivos de escores menores no escore total do QOLIE-31 e em várias dimensões. Anormalidade ao exame neurológico e politerapia com drogas antiepiléticas foram fatores negativos limitados a uma das dimensões função cognitiva e função social, respectivamente. A presença de comorbidade psiquiátrica e a maior frequência de crises foram os principais fatores a influenciar a qualidade de vida avaliada pelo QOLIE-31 em pacientes com epilepsia.
